NLRP3 and inflammatory bowel disease: In PSC patients with concurrent inflammatory bowel disease (IBD), gut microbiome-derived OMVs travel to the liver and trigger NLRP3 inflammasome activation in hepatic cells, exacerbating liver inflammation and fibrosis [69].